TempraMed Announces Upsize to Offering

TempraMed aims to raise up to C$1.6M via an upsized private placement.

What the company is saying

TempraMed Technologies Ltd. is communicating that it has increased the size of its previously announced non-brokered private placement, now seeking up to C$1,600,000 in gross proceeds. The offering will be split between up to C$600,000 in unsecured convertible debentures and up to C$1,000,000 in units, each unit comprising one common share and one warrant. The company highlights the warrant's exercise price of C$1.00, exercisable for 18 months post-closing, and the debenture's 10% annual interest rate with a one-year maturity. Conversion rights allow debenture holders to convert principal at $0.50 per share at any time before maturity, including accrued interest at maturity. Proceeds are earmarked for new inventory, product development, scaling global sales and marketing, and general working capital. The announcement emphasizes compliance with Canadian securities law, including a four-month and one day hold period, and clarifies that the securities are not registered for U.S. sale. The tone is factual and focused on transaction mechanics, with no operational or financial performance claims.

What the data suggests

The disclosed figures show TempraMed is seeking to raise up to C$1,600,000, split between up to C$600,000 in unsecured convertible debentures and up to C$1,000,000 in units. Each warrant in the units is exercisable at C$1.00 for 18 months after closing. Debentures carry a 10% annual interest rate, paid quarterly, and mature one year from issuance. Conversion is allowed at $0.50 per share at any time before maturity, with accrued interest also convertible at maturity. All securities are subject to a four-month and one day hold period. The offering is not yet closed and remains subject to CSE approval and required filings. No breakdown of how much will be allocated to each use of proceeds category is provided. There is no current or historical financial performance data, so the announcement is limited to the mechanics and terms of the proposed financing.

Analysis

The announcement is a factual, detailed disclosure of an upsized private placement, specifying the terms, amounts, and intended use of proceeds. The tone is positive but not promotional, and there are no exaggerated claims about future performance or impact. Most key claims are forward-looking (the offering is proposed, not closed; use of proceeds is intended, not realised), but all are standard for a financing update and are not aspirational beyond the mechanics of the offering. The capital intensity flag is true, as the company seeks to raise up to C$1.6M for growth initiatives, but there is no immediate earnings impact or operational milestone tied to this capital. The execution distance is near_term, as the next step is closing the offering and deploying funds, which typically occurs within months. There is no narrative inflation or overstatement; the language is proportionate to the facts disclosed.

Risk flags

• ●The offering is not yet closed and is contingent on CSE approval and the filing of all required documentation, introducing regulatory and execution risk. If approvals are delayed or investor demand is insufficient, the company may not raise the targeted funds.
• ●The use of proceeds is broadly stated—new inventory, product development, scaling sales and marketing, and working capital—without detailed allocation or milestones, making it difficult to assess the direct impact on future performance or capital efficiency.
• ●All securities are subject to a statutory hold period of four months and one day, which may limit liquidity for investors and could affect aftermarket trading dynamics.

Bottom line

TempraMed Technologies Ltd. is seeking up to C$1.6 million in new capital through an upsized private placement, with clear terms for both convertible debentures and units. The structure offers investors a 10% yield on debentures, conversion rights at $0.50 per share, and warrants exercisable at C$1.00, but all securities will be restricted for four months and one day. The offering is not yet finalized and depends on CSE approval and investor uptake, so there is no immediate capital inflow. No operational or financial performance data is disclosed, so the announcement is purely about the financing mechanism. The main takeaway is that TempraMed is positioning to fund growth initiatives, but execution risk remains until the offering is closed and proceeds are deployed.

Announcement summary

(CSE:VIVI) TempraMed Technologies Ltd. has announced an upsize to its previously disclosed non-brokered private placement, now referred to as the Upsized Offering. The Upsized Offering will consist of up to C$600,000 in unsecured convertible debentures and up to C$1,000,000 in units, for total aggregate gross proceeds of up to C$1,600,000. Each unit will include one common share and one share purchase warrant. Each warrant will entitle the holder to purchase one additional common share at a price of C$1.00 at any time up to 18 months after the closing date of the Upsized Offering. The unsecured convertible debentures will bear interest at a rate of 10% per annum, calculated monthly and payable quarterly in cash. The debentures will mature on the one-year anniversary of their issuance. The principal amount of each debenture may be converted into common shares at a conversion price of $0.50 per share by the holder at any time on or before the maturity date. On the maturity date, holders may convert the outstanding principal and any accrued and unpaid interest into shares at the same conversion price. The intended use of proceeds from the Upsized Offering is to fund new inventory, product development, scaling of the sales and marketing division globally, and for general working capital. All securities issued in connection with the Upsized Offering will be subject to a statutory hold period of four months and one day following issuance, in accordance with Canadian securities laws. The Upsized Offering is subject to approval by the CSE and the filing of all required documentation. The securities have not been and will not be registered under the United States Securities Act of 1933 or any state securities laws, and may not be offered or sold within the United States unless registered or exempt from registration.

Disagree with this article?